Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Novo Nordisk (CPSE:NOVO B) reported that its phase 3 HIBISCUS trial of etavopivat for sickle cell disease met both co primary endpoints.
The investigational therapy reduced vaso occlusive crisis events and improved haemoglobin response in trial participants.
The company plans to submit etavopivat for regulatory approval in the second half of 2026.
Novo Nordisk, widely associated with diabetes and obesity treatments, is using etavopivat to expand into blood disorders. For investors, sickle cell disease represents a different therapeutic area to watch, with a patient population that faces significant unmet medical needs and limited treatment options. This phase 3 readout gives CPSE:NOVO B another late stage asset that sits outside its core metabolic portfolio.
Looking ahead, the planned regulatory submission in 2026 represents a potential new chapter for Novo Nordisk’s pipeline mix. Developments for etavopivat, alongside recent news about a rival therapy, may inform how you assess the company’s position in rare diseases and the degree of diversification in its future revenue sources.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
CPSE:NOVO B Earnings & Revenue Growth as at Apr 2026
We’ve flagged 5 risks for Novo Nordisk. See which could impact your investment.
✅ Price vs Analyst Target: The DKK260.4 share price sits about 15% below the DKK307.7 analyst target range midpoint.
✅ Simply Wall St Valuation: Shares are flagged as trading around 66.1% below the platform’s estimated fair value.
✅ Recent Momentum: A 30 day return of about 9.7% suggests investors are already reacting to the current pipeline and news flow.
There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to Simply Wall St’s company report for the latest analysis of Novo Nordisk’s fair value.
📊 Positive phase 3 results for etavopivat add a late stage rare disease asset alongside the existing diabetes and obesity franchise.
📊 Watch upcoming regulatory interactions, competitive data in sickle cell disease, and how analysts factor potential revenue into their DKK307.7 target.
⚠️ The company carries a high level of debt and faces five flagged risks overall, so position sizing may matter if you are focused on downside protection.
For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis. Alternatively, you can visit the community page for Novo Nordisk to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com